

Molecular Diagnostics

ACCOUNT INFORMATION			
Account name: _____			
Address: _____		City: _____	State: _____
Zip code: _____	Ph: _____	Fax: _____	

Molecular Diagnostics Laboratory
 2330 Inwood Road, Suite EB3.304
 Dallas, Texas 75235
 LAB PHONE: 214-648-0960
 LAB FAX: 214-648-0967
 CUSTOMER SERVICE: 214-633-5227
 CLIA #: 45D0861764
 CAP #: 2664213



REQUIRED ORDER INFORMATION			
BILL TO: <input type="checkbox"/> Facility / Client <input type="checkbox"/> Patient / 3rd party – Billing information must be provided			
Patient Name: (Last, First, Middle) _____			
Mother's Name: (if infant) _____			
Date of Birth: _____	Sex: _____	Patient ID / MR#: _____	
Hospital Inpatient Y / N _____	Collection Date: _____	Collection Time: _____	AM : PM
Ordering Physician (Full Name): _____		NPI: _____	
Phone: _____	Pager: _____	FAX: _____	
Clinical Indication for Tests Ordered: _____			

PATIENT/3RD PARTY BILLING INFORMATION	
ICD-10 Code(s) _____	<input type="checkbox"/> Signed ABN included
Medicare patients with non-covered diagnoses must sign Advanced Beneficiary Notice (ABN) available at: www.veripathlabs.com or by calling customer service at 214-645-7057 or toll free 877-887-8136	
ICD-10 Codes applicable to each and every test requested should come only from the ordering physician, represent the reason for the test order at the time of order, and be supported by the patient's medical record. Physicians should order only tests that are medically necessary for the diagnosis or treatment of the patient. Tests ordered should be single laboratory tests appropriate for the patient's medical condition. Tests for screening purposes may be ordered, but may not be reimbursed.	
Insured/Responsible Party Name: (if different from patient-Last, First, Middle) _____	Date of Birth: _____
Patient's relationship: <input type="checkbox"/> Self <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent <input type="checkbox"/> Other	Responsible Party Address: (street, city, State, zip) _____
Sex: _____	Phone: _____

SPECIMEN INFORMATION	
<input type="checkbox"/> Whole Blood (EDTA preferred)	<input type="checkbox"/> Serum
<input type="checkbox"/> Plasma (EDTA preferred)	<input type="checkbox"/> Bone Marrow (EDTA preferred)
<input type="checkbox"/> ThinPrep® (Must be Endocervical)	<input type="checkbox"/> CSF
	<input type="checkbox"/> Swab in Viral Media
	<input type="checkbox"/> Urine
<input type="checkbox"/> Sorted Cells, source: _____	
<input type="checkbox"/> Fixed Paraffin Embedded Tissue	
Source: _____	Block #: _____
<input type="checkbox"/> Other: _____	

Employer's Name: _____	Employer's Phone: _____
Insurance Co. Name: _____	Insurance Co. Phone: _____
Insurance Co. Address: _____	
Policy #: _____	Group #: _____
<input type="checkbox"/> Medicare <input type="checkbox"/> HMO <input type="checkbox"/> Other <input type="checkbox"/> Medicaid <input type="checkbox"/> PPO	Member ID#: _____
Referral Authorization/Precertification #: _____	
Name: _____	Date/Time: _____

TESTS REQUESTED

MOLECULAR ONCOLOGY	
<input type="checkbox"/> B-Cell Clonality PCR	
<input type="checkbox"/> T-Cell Clonality PCR	
<input type="checkbox"/> BRAF mutations	
<input type="checkbox"/> EGFR mutations by sequencing	
<input type="checkbox"/> EGFR mutations, FDA approved PCR (FFPE)	
<input type="checkbox"/> ERBB2 mutations, lung cancer	
<input type="checkbox"/> IDH1/IDH2 mutations	
<input type="checkbox"/> FLT3 mutation	
<input type="checkbox"/> KIT in melanoma	
<input type="checkbox"/> KRAS mutation analysis	
<input type="checkbox"/> LOH for 1p/19q brain tumors	
<input type="checkbox"/> MEK1 mutations	
<input type="checkbox"/> NRAS mutations	
<input type="checkbox"/> PIK3CA mutations	
<input type="checkbox"/> TP53 mutations	
<input type="checkbox"/> Microsatellite instability (MSI) by PCR	
CANCER MUTATION PANELS	
<input type="checkbox"/> Colon: KRAS, NRAS, BRAF	
<input type="checkbox"/> Lung: EGFR, KRAS, PIK3CA, ERBB2, BRAF, NRAS, MEK, AKT	
<input type="checkbox"/> Melanoma: BRAF, C-KIT, NRAS	
<input type="checkbox"/> 50-gene Cancer Mutation Panel by NGS	

INFECTIOUS DISEASE by PCR	
<input type="checkbox"/> BK viral load	
<input type="checkbox"/> Chlamydia and Gonorrhoeae, Urine or Thin Prep	
<input type="checkbox"/> CMV viral load	
<input type="checkbox"/> EBV viral load	
<input type="checkbox"/> HCV viral load	
<input type="checkbox"/> HPV high risk with genotyping, cervical	
<input type="checkbox"/> HSV1 and HSV2	
<input type="checkbox"/> VZV	
<input type="checkbox"/> HHV-6 (HHV-6A qualitative; HHV-6b quantitative)	
<input type="checkbox"/> Vaginal Panel - BV, Candidiasis, Trichomoniasis	
TRANSPLANT ANALYSIS	
<input type="checkbox"/> Pre-Transplant STR analysis	
Donor Name _____	
Recipient Name _____	
<input type="checkbox"/> Post-Transplant STR Analysis	
GENETIC MUTATIONS Ethnicity _____	
<input type="checkbox"/> Factor II (Prothrombin) 20210 G>A G20210A	
<input type="checkbox"/> Factor 5 Leiden G1691A	
<input type="checkbox"/> MTHFR 677 C>T and 1298 A>C C677T and A1298C (C665T and A1286C)	
SPECIMEN CONTAMINATION ASSESSMENT	
<input type="checkbox"/> Mixed or contaminated FFPET (slides)	

LAB USE ONLY	Transport Container: _____	Total # of specimens: _____	Transport Conditions: _____	Destination: <input type="checkbox"/> Other _____	Initials: _____
	___Yellow ___Green ___Purple ___Syringe ___Conical ___Red ___Blue ___Cup		<input type="checkbox"/> Frozen <input type="checkbox"/> Slushy	<input type="checkbox"/> Coag <input type="checkbox"/> Cytogen <input type="checkbox"/> HemePath	
	___Trans Tube ___Block ___Slides ___Formalin ___Other: _____		<input type="checkbox"/> Refrig <input type="checkbox"/> Room Temp	<input type="checkbox"/> Flow <input type="checkbox"/> Hist <input type="checkbox"/> Mol Dx	